Please login to the form below

Not currently logged in
Email:
Password:

Micreos appoints chief medical officer

Dr Johan Frieling brings experience from Bayer and Genzyme

Micreos Dr Johan FrielingDutch biotech company Micreos has appointed Dr Johan Frieling as its new chief scientific officer.

In his new role Dr Frieling will be responsible for overseeing Micreos' antibiotic alternative, Staphefekt, as it begins clinical trials.

Mark Offerhaus, founder and chief executive officer of Micreos, said: “Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval.

“For us he is the ideal person to lead Staphefekt to market in the new indications.”

Dr Frieling has over 20 years of clinical development experience and has previously held senior positions at Bayer, Genzyme and Pharmasquire Consultancy.

He joins Micreos from LFB Biotechnologies where he served most recently as director of global clinical research, with responsibility for all development products at the company.

Dr Freiling said: “It's a great time to be joining Micreos … I look forward to sharing my knowledge and leading the clinical development of Staphefekt, ultimately helping a large cohort of patients across the globe.”

23rd March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics